cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.10826301
title: Experimental Repository for "Certifying Without Loss of Generality Reasoning in Solution-Improving Maximum Satisfiability"

description: Experimental repository for "Certifying Without Loss of Generality Reasoning in Solution-Improving Maximum Satisfiability".

The directory is structured as follows:



data: Data that has been processed into CSVs and the scripts to analyse the experiments.

plots: The plots generated from the data that are used in the paper.

raw_data: The raw data logs for the experiments and scripts to extract relevant data from the logs.

source_code: Source code for the checker VeriPB and the MaxSAT solver Pacose in the different variants used for the experiments. The Pacose version in PacoseMaxSATSolver-baseline is Pacose without proof logging, the version in PacoseMaxSATSolver-certified is Pacose with proof logging. Proof logging using only assumptions for the coarse convergence can be enabled via the option --WithAssumptions.


Install Requirements

To install and run the MaxSAT solver Pacose and the pseudo-Boolean proof checker VeriPB your need to have the following components installed:



Python 3.6.9 or higher with pip and setuptools installed

g++ 7.5.0 or higher

libgmp


These can be installed in Ubuntu / Debian via

sudo apt-get update && apt-get install \
        python3 \
        python3-pip \
        python3-dev \
        g++ \
        libgmp-dev
pip3 install --user \
        setuptools

How to Run?

The MaxSAT solver Pacose can be compiled using the install script in PacoseMaxSATSolver-certified:

./install

To run Pacose with proof logging, where the proof should be written to proof.pbp, run the following command in the PacoseMaxSATSolver-certified directory:

./bin/Pacose --proofFile proof.pbp instance.wcnf

The proof can be checked with VeriPB. To compile VeriPB run the following in the VeriPB directory:

pip install .

To check the proof with VeriPB, run the following inside the PacoseMaxSATSolver-certified directory:

veripb --wcnf instance.wcnf proof.pbp
DOI: 10.5281/zenodo.10826302
title: Experimental Repository for "Certifying Without Loss of Generality Reasoning in Solution-Improving Maximum Satisfiability"

description: Experimental repository for "Certifying Without Loss of Generality Reasoning in Solution-Improving Maximum Satisfiability".

The directory is structured as follows:



data: Data that has been processed into CSVs and the scripts to analyse the experiments.

plots: The plots generated from the data that are used in the paper.

raw_data: The raw data logs for the experiments and scripts to extract relevant data from the logs.

source_code: Source code for the checker VeriPB and the MaxSAT solver Pacose in the different variants used for the experiments. The Pacose version in PacoseMaxSATSolver-baseline is Pacose without proof logging, the version in PacoseMaxSATSolver-certified is Pacose with proof logging. Proof logging using only assumptions for the coarse convergence can be enabled via the option --WithAssumptions.


How to Run?

The MaxSAT solver Pacose can be compiled using the install script in PacoseMaxSATSolver-certified:

./install

To run Pacose with proof logging, where the proof should be written to proof.pbp, run the following command in the PacoseMaxSATSolver-certified directory:

./bin/Pacose --proofFile proof.pbp instance.wcnf

The proof can be checked with VeriPB. To compile VeriPB run the following in the VeriPB directory:

pip install .

To check the proof with VeriPB, run the following inside the PacoseMaxSATSolver-certified directory:

veripb --wcnf instance.wcnf proof.pbp
DOI: 10.5281/zenodo.12591387
title: Experimental Repository for "Certifying Without Loss of Generality Reasoning in Solution-Improving Maximum Satisfiability"

description: Experimental repository for "Certifying Without Loss of Generality Reasoning in Solution-Improving Maximum Satisfiability".

The directory is structured as follows:



data: Data that has been processed into CSVs and the scripts to analyse the experiments.

plots: The plots generated from the data that are used in the paper.

raw_data: The raw data logs for the experiments and scripts to extract relevant data from the logs.

source_code: Source code for the checker VeriPB and the MaxSAT solver Pacose in the different variants used for the experiments. The Pacose version in PacoseMaxSATSolver-baseline is Pacose without proof logging, the version in PacoseMaxSATSolver-certified is Pacose with proof logging. Proof logging using only assumptions for the coarse convergence can be enabled via the option --WithAssumptions.


How to Run?

The MaxSAT solver Pacose can be compiled using the install script in PacoseMaxSATSolver-certified:

./install

To run Pacose with proof logging, where the proof should be written to proof.pbp, run the following command in the PacoseMaxSATSolver-certified directory:

./bin/Pacose --proofFile proof.pbp instance.wcnf

The proof can be checked with VeriPB. To compile VeriPB run the following in the VeriPB directory:

pip install .

To check the proof with VeriPB, run the following inside the PacoseMaxSATSolver-certified directory:

veripb --wcnf instance.wcnf proof.pbp
DOI: 10.5281/zenodo.13912714
title: Experimental Repository for "Certifying Without Loss of Generality Reasoning in Solution-Improving Maximum Satisfiability"

description: Experimental repository for "Certifying Without Loss of Generality Reasoning in Solution-Improving Maximum Satisfiability".

The directory is structured as follows:



data: Data that has been processed into CSVs and the scripts to analyse the experiments.

plots: The plots generated from the data that are used in the paper.

raw_data: The raw data logs for the experiments and scripts to extract relevant data from the logs.

source_code: Source code for the checker VeriPB and the MaxSAT solver Pacose in the different variants used for the experiments. The Pacose version in PacoseMaxSATSolver-baseline is Pacose without proof logging, the version in PacoseMaxSATSolver-certified is Pacose with proof logging. Proof logging using only assumptions for the coarse convergence can be enabled via the option --WithAssumptions.


Install Requirements

To install and run the MaxSAT solver Pacose and the pseudo-Boolean proof checker VeriPB your need to have the following components installed:



Python 3.6.9 or higher with pip and setuptools installed

g++ 7.5.0 or higher

libgmp


These can be installed in Ubuntu / Debian via

sudo apt-get update && apt-get install \
        python3 \
        python3-pip \
        python3-dev \
        g++ \
        libgmp-dev
pip3 install --user \
        setuptools

How to Run?

The MaxSAT solver Pacose can be compiled using the install script in PacoseMaxSATSolver-certified:

./install

To run Pacose with proof logging, where the proof should be written to proof.pbp, run the following command in the PacoseMaxSATSolver-certified directory:

./bin/Pacose --proofFile proof.pbp instance.wcnf

The proof can be checked with VeriPB. To compile VeriPB run the following in the VeriPB directory:

pip install .

To check the proof with VeriPB, run the following inside the PacoseMaxSATSolver-certified directory:

veripb --wcnf instance.wcnf proof.pbp
DOI: 10.6084/m9.figshare.20311602
title: Effect of dexmedetomidine for prevention of acute kidney injury after cardiac surgery: an updated systematic review and meta-analysis

description: Acute kidney injury (AKI) is a serious complication related to cardiac surgery. Several studies have been conducted to investigate the effect of dexmedetomidine administration on AKI prevention. To assess if dexmedetomidine is associated with a protective effect of renal function after cardiac surgery. And the aim of conducting this meta-analysis is to summarize the literature and determine the clinical utility of dexmedetomidine administration in patients undergoing cardiac surgery. PubMed, Cochrane Library, and EMBASE databases were comprehensively searched for all randomized controlled trials (RCTs) published before 1 December, 2021 that investigated the effect of dexmedetomidine on AKI prevention. Our analysis included 16 studies involving 2148 patients. Compared with the control group, dexmedetomidine administration significantly reduced AKI incidence (OR, 0.47; 95% CI, 0.36–0.61; <i>p</i> &lt;  0.00001; <i>I</i><sup>2</sup> = 26%) and the length of stay in the intensive care unit (ICU) but did not alter mortality rate, length of stay in the hospital, and mechanical ventilation time. Furthermore, the incidence of delirium among patients treated with dexmedetomidine was significantly decreased. Dexmedetomidine administration has a positive effect on preventing AKI and postoperative delirium after cardiac surgery and significantly reduces the length of stay in the ICU.
DOI: 10.6084/m9.figshare.20311602.v1
title: Effect of dexmedetomidine for prevention of acute kidney injury after cardiac surgery: an updated systematic review and meta-analysis

description: Acute kidney injury (AKI) is a serious complication related to cardiac surgery. Several studies have been conducted to investigate the effect of dexmedetomidine administration on AKI prevention. To assess if dexmedetomidine is associated with a protective effect of renal function after cardiac surgery. And the aim of conducting this meta-analysis is to summarize the literature and determine the clinical utility of dexmedetomidine administration in patients undergoing cardiac surgery. PubMed, Cochrane Library, and EMBASE databases were comprehensively searched for all randomized controlled trials (RCTs) published before 1 December, 2021 that investigated the effect of dexmedetomidine on AKI prevention. Our analysis included 16 studies involving 2148 patients. Compared with the control group, dexmedetomidine administration significantly reduced AKI incidence (OR, 0.47; 95% CI, 0.36–0.61; <i>p</i> &lt;  0.00001; <i>I</i><sup>2</sup> = 26%) and the length of stay in the intensive care unit (ICU) but did not alter mortality rate, length of stay in the hospital, and mechanical ventilation time. Furthermore, the incidence of delirium among patients treated with dexmedetomidine was significantly decreased. Dexmedetomidine administration has a positive effect on preventing AKI and postoperative delirium after cardiac surgery and significantly reduces the length of stay in the ICU.
DOI: 10.6084/m9.figshare.19432116
title: Efficacy and safety of expanded hemodialysis in hemodialysis patients: a meta-analysis and systematic review

description: Expanded hemodialysis (HDx) is a new dialysis modality, but a systematic review of the clinical effects of using HDx is lacking. This systematic review and meta-analysis aimed to assess the efficacy and safety of HDx for hemodialysis (HD) patients. PubMed, the Cochrane library, and EMBASE databases were systematically searched for prospective interventional studies comparing the efficacy and safety of HDx with those of high flux HD or HDF in HD patients. Eighteen trials including a total of 853 HD patients were enrolled. HDx increased the reduction ratio (RR) of β2-microglobulin (SMD 6.28%, 95% CI 0.83, 1.73, <i>p</i> = .02), κFLC (SMD 15.86%, 95% CI 6.96, 24.76, <i>p</i> = .0005), and λFLC (SMD 22.42%, 95% CI, 17.95, 26.88, <i>p</i> &lt; .0001) compared with high flux HD. The RR of β2-microglobulin in the HDx group was lower than that in the HDF group (SMD −3.53%, 95% CI −1.16, −1.9, <i>p</i> &lt; .0001). HDx increased the RRs of κFLC (SMD 1.34%, 95% CI 0.52, 2.16, <i>p</i> = .001) and λFLC (SMD 7.28%, 95% CI 1.08, 13.48, <i>p</i> = .02) compared to HDF. There was no significant difference in albumin loss into the dialysate between the HDx and HDF groups (SMD 0.35 g/session, 95% CI −2.38, 3.09, <i>p</i> = .8). This meta-analysis indicated that compared with high-flux HD and HDF, HDx can increase the clearance of medium and large-molecular-weight uremic toxins. And it does not increase the loss of albumin compared with HDF.
DOI: 10.6084/m9.figshare.19432116.v3
title: Efficacy and safety of expanded hemodialysis in hemodialysis patients: a meta-analysis and systematic review

description: Expanded hemodialysis (HDx) is a new dialysis modality, but a systematic review of the clinical effects of using HDx is lacking. This systematic review and meta-analysis aimed to assess the efficacy and safety of HDx for hemodialysis (HD) patients. PubMed, the Cochrane library, and EMBASE databases were systematically searched for prospective interventional studies comparing the efficacy and safety of HDx with those of high flux HD or HDF in HD patients. Eighteen trials including a total of 853 HD patients were enrolled. HDx increased the reduction ratio (RR) of β2-microglobulin (SMD 6.28%, 95% CI 0.83, 1.73, <i>p</i> = .02), κFLC (SMD 15.86%, 95% CI 6.96, 24.76, <i>p</i> = .0005), and λFLC (SMD 22.42%, 95% CI, 17.95, 26.88, <i>p</i> &lt; .0001) compared with high flux HD. The RR of β2-microglobulin in the HDx group was lower than that in the HDF group (SMD −3.53%, 95% CI −1.16, −1.9, <i>p</i> &lt; .0001). HDx increased the RRs of κFLC (SMD 1.34%, 95% CI 0.52, 2.16, <i>p</i> = .001) and λFLC (SMD 7.28%, 95% CI 1.08, 13.48, <i>p</i> = .02) compared to HDF. There was no significant difference in albumin loss into the dialysate between the HDx and HDF groups (SMD 0.35 g/session, 95% CI −2.38, 3.09, <i>p</i> = .8). This meta-analysis indicated that compared with high-flux HD and HDF, HDx can increase the clearance of medium and large-molecular-weight uremic toxins. And it does not increase the loss of albumin compared with HDF.
DOI: 10.6084/m9.figshare.21517526
title: Dynamic changes of neutrophil-to-lymphocyte ratio in brain-dead donors and delayed graft function in kidney transplant recipients

description: Neutrophil-to-lymphocyte ratio (NLR) is a simple parameter implying the inflammatory status. We aimed to explore the association of brain-dead donor NLR change with delayed graft function (DGF) in kidney transplant recipients. We retrospectively analyzed the data on 102 adult brain-dead donors and their corresponding 199 kidney transplant recipients (2018 − 2021). We calculated ΔNLR by subtracting the NLR before evaluating brain death from the preoperative NLR. Increasing donor NLR was defined as ΔNLR &gt; 0. Forty-four (22%) recipients developed DGF after transplantation. Increasing donor NLR was significantly associated with the development of DGF in recipients (OR 2.8, 95% CI 1.2 − 6.6; <i>p</i> = .018), and remained significant (OR 2.6, 95% CI 1.0 − 6.4; <i>p</i> = .040) after adjustment of confounders including BMI, hypertension, diabetes, and the occurrence of cardiac arrest. When acute kidney injury (AKI) was included in the multivariable analysis, increasing donor NLR lost its independent correlation with DGF, while AKI remained an independent risk factor of recipient DGF (OR 4.5, 95% CI 2.7 − 7.6; <i>p</i> &lt; .001). The area under the curve of combined increasing NLR and AKI in donors (0.873) for predicting DGF was superior to increasing donor NLR (0.625, <i>p</i> = .015) and AKI alone (0.859, <i>p</i> &lt; .001). Dynamic changes of donor NLR are promising in predicting post-transplant DGF. It will assist clinicians in the early recognition and management of renal graft dysfunction. Validation of this new biomarker in a large study is needed.
DOI: 10.6084/m9.figshare.21517526.v1
title: Dynamic changes of neutrophil-to-lymphocyte ratio in brain-dead donors and delayed graft function in kidney transplant recipients

description: Neutrophil-to-lymphocyte ratio (NLR) is a simple parameter implying the inflammatory status. We aimed to explore the association of brain-dead donor NLR change with delayed graft function (DGF) in kidney transplant recipients. We retrospectively analyzed the data on 102 adult brain-dead donors and their corresponding 199 kidney transplant recipients (2018 − 2021). We calculated ΔNLR by subtracting the NLR before evaluating brain death from the preoperative NLR. Increasing donor NLR was defined as ΔNLR &gt; 0. Forty-four (22%) recipients developed DGF after transplantation. Increasing donor NLR was significantly associated with the development of DGF in recipients (OR 2.8, 95% CI 1.2 − 6.6; <i>p</i> = .018), and remained significant (OR 2.6, 95% CI 1.0 − 6.4; <i>p</i> = .040) after adjustment of confounders including BMI, hypertension, diabetes, and the occurrence of cardiac arrest. When acute kidney injury (AKI) was included in the multivariable analysis, increasing donor NLR lost its independent correlation with DGF, while AKI remained an independent risk factor of recipient DGF (OR 4.5, 95% CI 2.7 − 7.6; <i>p</i> &lt; .001). The area under the curve of combined increasing NLR and AKI in donors (0.873) for predicting DGF was superior to increasing donor NLR (0.625, <i>p</i> = .015) and AKI alone (0.859, <i>p</i> &lt; .001). Dynamic changes of donor NLR are promising in predicting post-transplant DGF. It will assist clinicians in the early recognition and management of renal graft dysfunction. Validation of this new biomarker in a large study is needed.
DOI: 10.18738/t8/uoes4s/eo2lei
title: timestamps.txt
DOI: 10.6084/m9.figshare.19342663.v1
title: Feasibility of a break-in period of less than 24 hours for urgent start peritoneal dialysis: a multicenter study

description: Urgent start peritoneal dialysis (USPD) is an effective therapeutic method for end-stage renal disease (ESRD). However, whether it is safe to initiate peritoneal dialysis (PD) within 24 h unclear. We examined the short-term outcomes of a break-in period (BI) of 24 h for patients undergoing USPD. This real-world, multicenter, retrospective cohort study evaluated USPD patients from five centers from January 2013 to August 2020. Patients were divided into BI ≤ 24 h or BI &gt; 24 h groups. The Primary outcomes included incidence of mechanical and infectious complications. The secondary outcome was technique failure. Moreover, we presented a subgroup analysis for patients who did not receive temporary hemodialysis (HD). A total of 871 USPD patients were included: 470 in the BI ≤ 24 h and 401 in the BI &gt; 24 h groups. Mechanical and infectious complications did not differ between the two groups across the follow-up timepoints (2 weeks, 1 month, 3 months, and 6 months) (<i>p</i> &gt; 0.05). Multiple logistic regression analysis revealed that BI ≤ 24 h was not an independent risk factor for mechanical complications, catheter migration, or infectious complications (<i>p</i> &gt; 0.05). A BI ≤ 24 h was not an independent significant risk factor for technique failure by multivariate Cox regression analysis (<i>p</i> &gt; 0.05). The subgroup analysis of patients who did not receive temporary HD returned the same results. Initiating PD within 24 h of catheter insertion was not associated with increased mechanical complications, infectious complications, or technique failures.
DOI: 10.6084/m9.figshare.19342663
title: Feasibility of a break-in period of less than 24 hours for urgent start peritoneal dialysis: a multicenter study

description: Urgent start peritoneal dialysis (USPD) is an effective therapeutic method for end-stage renal disease (ESRD). However, whether it is safe to initiate peritoneal dialysis (PD) within 24 h unclear. We examined the short-term outcomes of a break-in period (BI) of 24 h for patients undergoing USPD. This real-world, multicenter, retrospective cohort study evaluated USPD patients from five centers from January 2013 to August 2020. Patients were divided into BI ≤ 24 h or BI &gt; 24 h groups. The Primary outcomes included incidence of mechanical and infectious complications. The secondary outcome was technique failure. Moreover, we presented a subgroup analysis for patients who did not receive temporary hemodialysis (HD). A total of 871 USPD patients were included: 470 in the BI ≤ 24 h and 401 in the BI &gt; 24 h groups. Mechanical and infectious complications did not differ between the two groups across the follow-up timepoints (2 weeks, 1 month, 3 months, and 6 months) (<i>p</i> &gt; 0.05). Multiple logistic regression analysis revealed that BI ≤ 24 h was not an independent risk factor for mechanical complications, catheter migration, or infectious complications (<i>p</i> &gt; 0.05). A BI ≤ 24 h was not an independent significant risk factor for technique failure by multivariate Cox regression analysis (<i>p</i> &gt; 0.05). The subgroup analysis of patients who did not receive temporary HD returned the same results. Initiating PD within 24 h of catheter insertion was not associated with increased mechanical complications, infectious complications, or technique failures.
DOI: 10.6084/m9.figshare.21908493
title: The role of lung ultrasonography in the assessment of overhydration in maintenance hemodialysis patients

description: Existed methods like biochemical markers improve the accuracy of fluid evaluation for the maintenance hemodialysis patients, but none of them has become the gold standard. This study aimed to evaluate the potential of lung ultrasonography as a useful tool for monitoring the volume status of the patients. A total of 88 patients undergoing maintenance hemodialytic were enrolled in this prospective observational study. Patients were divided into three groups: overhydration (OH), normohydration, and hypohydration according to bioimpedance spectroscopy. Lung ultrasonography parameters, echocardiography parameters, and clinical characteristics of three groups were analyzed. After an average follow-up of 433 days, all-cause mortality among groups was compared. The total number of lung comets was statistically reduced in patients after dialysis (<i>Z</i>= −6.891, <i>p</i> &lt; 0.001). This reduction was related to ΔOH (OH – Δ<i>W</i> (the weight gain from dry weight)) and echocardiographic parameters, which proved the relationship among the comet-tail, hydration status of body and cardiac performance. The Kappa consistency test showed that lung ultrasonography and bioelectrical spectroscopy had moderate consistency. ROC analysis showed that the best cut-point of lung comet is 13. The pre-/post-dialysis lung comet-tail, cardiac function and total body impedance with all-cause mortality was investigated. Kaplan–Meier’s analysis revealed that the all-cause mortality was higher in lung congestion patients. This study proposes a potentially reliable lung ultrasonography method for estimating fluids overload, which also has implication value of all-cause mortality.